Scholars@Duke

ACRIN 6684: Multicenter phase II assessment of tumor hypoxia in glioblastoma using 18F-Fluoromisonidazole (FMISO) PET and MRI

Publication ,  Conference
Fink, J; Zhang, Z; Elizabeth, G; Muzi, M; Kostakoglu, L; Mintz, A; Eikmann, E; Barboriak, D; Mankoff, D
Published in: JOURNAL OF NUCLEAR MEDICINE
2015

Duke Scholars

Daniel P. Barboriak
Author Daniel P. Barboriak Radiology, Neuroradiology

Published In

JOURNAL OF NUCLEAR MEDICINE

EISSN

1535-5667

ISSN

0161-5505

Publication Date

2015

Volume

56

Issue

3

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 3202 Clinical sciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Fink, J., Zhang, Z., Elizabeth, G., Muzi, M., Kostakoglu, L., Mintz, A., … Mankoff, D. (2015). ACRIN 6684: Multicenter phase II assessment of tumor hypoxia in glioblastoma using 18F-Fluoromisonidazole (FMISO) PET and MRI. In JOURNAL OF NUCLEAR MEDICINE (Vol. 56).
Fink, James, Zheng Zhang, Gertstner Elizabeth, Mark Muzi, Lale Kostakoglu, Akiva Mintz, Edward Eikmann, Daniel Barboriak, and David Mankoff. “ACRIN 6684: Multicenter phase II assessment of tumor hypoxia in glioblastoma using 18F-Fluoromisonidazole (FMISO) PET and MRI.” In JOURNAL OF NUCLEAR MEDICINE, Vol. 56, 2015.
Fink J, Zhang Z, Elizabeth G, Muzi M, Kostakoglu L, Mintz A, et al. ACRIN 6684: Multicenter phase II assessment of tumor hypoxia in glioblastoma using 18F-Fluoromisonidazole (FMISO) PET and MRI. In: JOURNAL OF NUCLEAR MEDICINE. 2015.
Fink J, Zhang Z, Elizabeth G, Muzi M, Kostakoglu L, Mintz A, Eikmann E, Barboriak D, Mankoff D. ACRIN 6684: Multicenter phase II assessment of tumor hypoxia in glioblastoma using 18F-Fluoromisonidazole (FMISO) PET and MRI. JOURNAL OF NUCLEAR MEDICINE. 2015.

Published In

JOURNAL OF NUCLEAR MEDICINE

EISSN

1535-5667

ISSN

0161-5505

Publication Date

2015

Volume

56

Issue

3

Related Subject Headings

  • Nuclear Medicine & Medical Imaging
  • 3202 Clinical sciences
  • 1103 Clinical Sciences